Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy
- PMID: 33306220
- DOI: 10.1002/adma.202007247
Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy
Abstract
Tumor immunometabolism contributes substantially to tumor proliferation and immune cell activity, and thus plays a crucial role in the efficacy of cancer immunotherapy. Modulation of immunometabolism to boost cancer immunotherapy is mostly based on small-molecule inhibitors, which often encounter the issues of off-target adverse effects, drug resistance, and unsustainable response. In contrast, enzymatic therapeutics can potentially bypass these limitations but has been less exploited. Herein, an organic polymer nanoenzyme (SPNK) with near-infrared (NIR) photoactivatable immunotherapeutic effects is reported for photodynamic immunometabolic therapy. SPNK is composed of a semiconducting polymer core conjugated with kynureninase (KYNase) via PEGylated singlet oxygen (1 O2 ) cleavable linker. Upon NIR photoirradiation, SPNK generates 1 O2 not only to exert photodynamic effect to induce the immunogenic cell death of cancer, but also to unleash KYNase and trigger its activity to degrade the immunosuppressive kynurenine (Kyn). Such a combinational effect mediated by SPNK promotes the proliferation and infiltration of effector T cells, enhances systemic antitumor T cell immunity, and ultimately permits inhibition of both primary and distant tumors in living mice. Therefore, this study provides a promising photodynamic approach toward remotely controlled enzymatic immunomodulation for improved anticancer therapy.
Keywords: cancer therapy; immunotherapy; organic nanoparticles; photoactivation; photodynamic therapy.
© 2020 Wiley-VCH GmbH.
References
-
- a) H. Yang, C. Bueso-Ramos, C. DiNardo, M. R. Estecio, M. Davanlou, Q. Geng, Z. Fang, M. Nguyen, S. Pierce, Y. Wei, S. Parmar, J. Cortes, H. Kantarjian, G. Garcia-Manero, Leukemia 2014, 28, 1280;
-
- b) D. Atanackovic, T. Luetkens, N. Kröger, Leukemia 2014, 28, 993;
-
- c) T. Kozako, M. Yoshimitsu, H. Fujiwara, I. Masamoto, S. Horai, Y. White, M. Akimoto, S. Suzuki, K. Matsushita, K. Uozumi, C. Tei, N. Arima, Leukemia 2009, 23, 375.
-
- a) D. O'Sullivan, D. E. Sanin, E. J. Pearce, E. L. Pearce, Nat. Rev. Immunol. 2019, 19, 324;
-
- b) M. Binnewies, E. W. Roberts, K. Kersten, V. Chan, D. F. Fearon, M. Merad, L. M. Coussens, D. I. Gabrilovich, S. Ostrand-Rosenberg, C. C. Hedrick, R. H. Vonderheide, M. J. Pittet, R. K. Jain, W. Zou, T. K. Howcroft, E. C. Woodhouse, R. A. Weinberg, M. F. Krummel, Nat. Med. 2018, 24, 541.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous